On April 7th, FDA Commissioner Margaret Hamburg engaged in a public discussion at the Alzheimer’s Association Advocacy forum with the organization’s President and CEO, Harry Johns. They discussed the FDA’s role in helping advance Alzheimer’s disease research and new treatment options.
Commissioner Hamburg highlighted CAMD as an example of the FDA’s support for public private partnerships, “We are working with the Coalition Against Major Disease (CAMD) to develop novel biomarkers to signal the onset of the disease and clinical-trial goals through the agency’s Drug Development Tool Qualification process, and have recently endorsed a clinical trial simulation tool they have developed. These represent just a few of our many collaborations within the Alzheimer’s disease field.” See more at: http://blogs.fda.gov/fdavoice/index.php/2014/04/recognizing-those-who-strive-to-vanquish-alzheimers-disease/#sthash.rfw54w80.dpuf